Biopharma Quarterly Dealmaking Statistics, Q4 2018
A look at financing, M&A and alliance activity October-December 2018
At $10.9bn, biopharma financing was at its lowest quarter of the year. GSK’s $5.1bn acquisition of oncology player Tesaro led M&As. And 13 partnerships exceeded the $1bn mark, led by two agreements focused on RNAi.
You may also be interested in...
Nearly two-thirds of the 67 drug developers that launched an IPO in 2018 were trading below their offering price at the end of the year, bringing the average return to -7.5%. Even so, biopharma companies continue to line up for a US stock market debut.
Allying itself with US biotech Agenus underscores Gilead's oncology ambitions, which incoming CEO-designate Daniel O'Day must make good on.
Bristol-Myers Squibb has joined the big pharma trend of divesting non-core assets to focus on high-margin prescription drugs by agreeing to sell over-the-counter drugs business UPSA for $1.6bn to Japanese healthcare firm Taisho Pharmaceutical.